B-Cell Antigen Valency Control for IgM and IgG Response Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for studying B-cell autoimmunity in transgenic mouse models are limited by the use of high-affinity mutated autoreactive BCRs, which create atypical B cell development and monospecific repertoires, and fail to account for the relevance of antigen valency and form in autoimmune diseases.
Innovation Solution
A composition comprising monovalent and polyvalent antigen particles, where the monovalent particle induces a protective IgM response and the polyvalent particle induces a strong IgG response, with a controlled ratio to modulate B-cell immunity, using specific ratios of soluble and complexed antigens to target B-cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high-affinity mutated autoreactive BCRs are used in transgenic mouse models, then B-cell development can be studied, but atypical B cell development and monospecific repertoires are created
Solution Approach 1:
The invention changes the parameters of antigen presentation by using different valencies (monovalent vs. polyvalent antigens) and forms (soluble vs. membrane-bound) to modulate B-cell responses. This allows studying diverse B-cell repertoires without requiring transgenic manipulation, thereby maintaining repertoire versatility while enabling reliable development studies.
2Productivity
If transgenic mouse models are used to study B-cell autoimmunity, then research can be conducted, but the antigens lack relevance to known autoimmune diseases and do not adequately address antigen valency and form
Solution Approach 1:
Instead of using transgenic models with artificial antigens, the invention copies and presents native autoantigens (such as insulin, GAD65, myelin basic protein) in their natural valency and form configurations. This allows research to be conducted while maintaining direct relevance to actual autoimmune diseases.
3Reliability
If monovalent antigenic structures are used, then IgG responses can be suppressed and protective IgM responses induced, but the ability to induce strong IgG responses is reduced
Solution Approach 1:
The invention employs dynamic control of antigen valency, allowing the system to switch between monovalent and polyvalent antigen presentation depending on the desired immune response. This dynamic approach enables selective induction of IgM or IgG responses based on therapeutic needs, rather than being fixed in one mode.
4Quantity of substance
If polyvalent antigenic structures are used, then strong IgG responses are induced, but the ability to induce protective IgM responses is reduced
Solution Approach 1:
The invention employs dynamic control of antigen valency, allowing the system to switch between monovalent and polyvalent antigen presentation depending on the desired immune response. This dynamic approach enables selective induction of IgM or IgG responses based on therapeutic needs, rather than being fixed in one mode.
Data Source
AI summary
The invention pertains to methods and means for the targeted modulation of B-cell mediated immune responses by bringing into contact a B-cell with a specific ratio of soluble single monovalent antigens and complexed multivalent antigens. The targeted modulation of B-cell immunity can be used in mammals for the diagnosis and therapy of various conditions associated with antibody-mediated immunity. Such conditions include proliferative disorders such as cancer, autoimmune disorders, pathogenic infections, inflammatory diseases, allergies and food intolerances. The invention is predicated on the observation that complexed multivalent antigenic structures induce a strong IgG type antibody B-cell response while surprisingly monovalent antigenic structures harbour the ability to suppress such IgG responses, or even induce in the case of autoantigens protective IgM responses. The invention in this regard offers methods, compositions, therapeutics, diagnostics and food additives.